{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-174540","form_type":"8-K","ticker":"CPRX","cik":"0001369568","company_name":"CATALYST PHARMACEUTICALS, INC.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.828018+00:00","generated_at":"2026-05-17T19:00:59.248611+00:00","sec_items":["8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Catalyst Pharma reports Q2 2025 revenue of $146.6M (+19.4% YoY); GAAP net income $52.1M","bullets":["FIRDAPSE Q2 net revenue $84.8M (+9.7% YoY); first-half 2025 net revenue $168.6M (+16.9% YoY).","AGAMREE Q2 net revenue $27.4M (+212.9% YoY); first-half net revenue $49.4M (+398.0% YoY).","FYCOMPA Q2 net revenue $34.3M (-6.0% YoY due to generic entry post LOE).","Non-GAAP diluted EPS $0.68, up from $0.56 in Q2 2024; cash $652.8M, no funded debt.","Reaffirmed FY2025 total revenue guidance of $545M to $565M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-174540","json":"https://secwatch.observer/filing/0001193125-25-174540.json","markdown":"https://secwatch.observer/filing/0001193125-25-174540.md","text":"https://secwatch.observer/filing/0001193125-25-174540.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1369568/000119312525174540/0001193125-25-174540-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1369568/000119312525174540/d941750d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:00:59.248611+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}